Cargando…
Lentiviral vectors can be used for full-length dystrophin gene therapy
Duchenne Muscular Dystrophy (DMD) is caused by a lack of dystrophin expression in patient muscle fibres. Current DMD gene therapy strategies rely on the expression of internally deleted forms of dystrophin, missing important functional domains. Viral gene transfer of full-length dystrophin could res...
Autores principales: | Counsell, John R., Asgarian, Zeinab, Meng, Jinhong, Ferrer, Veronica, Vink, Conrad A., Howe, Steven J., Waddington, Simon N., Thrasher, Adrian J., Muntoni, Francesco, Morgan, Jennifer E., Danos, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427806/ https://www.ncbi.nlm.nih.gov/pubmed/28250438 http://dx.doi.org/10.1038/s41598-017-00152-5 |
Ejemplares similares
-
Lentiviral vectors can be used for full-length dystrophin gene therapy
por: Counsell, John R., et al.
Publicado: (2017) -
Erratum: Lentiviral vectors can be used for full-length dystrophin gene therapy
por: Counsell, John R., et al.
Publicado: (2017) -
Optimized lentiviral vector to restore full-length dystrophin via a cell-mediated approach in a mouse model of Duchenne muscular dystrophy
por: Meng, Jinhong, et al.
Publicado: (2022) -
Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy
por: Meng, Jinhong, et al.
Publicado: (2016) -
Effects of Mini-Dystrophin on Dystrophin-Deficient, Human Skeletal Muscle-Derived Cells
por: Meng, Jinhong, et al.
Publicado: (2020)